Active Filter(s):
Details:
Titan has acquired JT Pharma's kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2020